A Review on Application of Novel Drug Delivery Systems for the N-Acetylcysteine

Abstract

NDDS technologies are transforming the therapeutic application of potent antioxidant N-acetylcysteine (NAC), a potent anti-inflammatory agent. These technologies improve NAC's pharmacokinetic profiles, focusing on selective activity areas and enabling sustained release. They include liposomes, hydrogels, microspheres, nanoparticles, and nanostructured carriers, aiming to increase bioavailability, protect NAC from degradation, and deliver controlled release for maximum therapeutic benefits and minimal side effects. The therapeutic potential of nanoparticles (NAC) in neurological diseases is being explored, with the potential to inhibit inflammatory pathways, neutralize reactive oxygen species, and affect cell survival. Technological developments, such as targeted delivery platforms and stimuli-responsive devices, are being explored to enhance NAC therapies. Personalized medicine is also crucial for maximizing NAC therapies. This review discusses the therapeutic potential of NAC-loaded NDDS, highlighting the need for clinical trials, preclinical studies, and Good Manufacturing Practice compliance. It also highlights the potential for NAC in NDDS to expand into other therapeutic fields, despite challenges in regulatory approval and patient acceptance.

Keywords

Introduction

Figure 1: Molecular Mechanism of Action of N- Acetylcysteine

The effectiveness of NAC delivery to specific areas of action is still a bottleneck, even though such mechanisms are well documented.

Importance of NAC in Emerging Therapeutic Areas:

NAC is a viable option for NDDS integration due to its broad-spectrum pharmacological activity. NDDS has the potential to transform the use of NAC in the following therapeutic areas:

• Neurological Disorders: Although NAC has poor permeability through the BBB, NDDS could help improve its ability to cross over into the central nervous system and thus enhance its efficacy in neurodegenerative diseases such as Parkinson's and Alzheimer's.
• Cancer: The antioxidant properties of NAC can modulate oxidative stress in tumour microenvironments. Targeted delivery by NDDS, however, may maximize its anticancer potential with minimal interference to conventional treatments.
• Respiratory Diseases: NAC can be delivered directly to the lungs using inhalable NDDS, such as aerosols and dry powder inhalers, maximizing its anti-inflammatory and mucolytic properties.
• Wound Healing and Tissue Regeneration: NAC is beneficial for tissue engineering because of its anti-inflammatory and antioxidant properties. The use of controlled-release hydrogels and nanogels may make local and sustained delivery to wounds or implants feasible.
• Metabolic Disorders: These two properties make NAC quite useful for tissue engineering; perhaps the use of controlled-release hydrogels and nanogels may make local and sustained delivery to wounds or implants feasible.(2)

Challenges in NAC Delivery

The effective use of NAC in diverse therapeutic contexts is constrained by several limitations:

Figure 2: Challenges in Conventional Drug Delivery

Innovative drug delivery methods that can improve NAC's stability, bioavailability, and therapeutic accuracy while reducing possible side effects are needed to address these issues.

Rationale for Integrating NAC with NDDS

It is clinically necessary, and not only a technical achievement, to integrate NAC with NDDS. Using the benefits of NDDS and surmounting the inherent drawbacks of NAC, it is possible to:

• Include illnesses with unmet medical needs in the list of NAC's therapeutic indications.
• Improve patient compliance by lowering the necessary dosage and administration frequency.
• With proper administration, diminish systemic side effects and increase on-target effects.

NDDS align with the more general trends in personalized medicine, which emphasize the adjustment of therapies to meet the needs of each patient. NAC-based NDDS may raise the standards of precision therapeutics.

The purpose of this review is to provide a comprehensive understanding of the integration of NAC into novel drug delivery systems. It will discuss various types of NDDS, how they function, and how they are applied in different therapeutic contexts. (3)

1. Novel drug delivery systems for NAC

N-acetyl cysteine (NAC) is regarded as one of the most potent therapeutic agents due to its antioxidant, mucolytic, and anti-inflammatory properties. Its application extends to encompass a variety of conditions including respiratory diseases, neurodegenerative disorders, and oncology.

Antioxidant and Anti-inflammatory Effects: NAC, a crucial tripeptide, is vital in therapeutic applications as it replenishes intracellular glutathione (GSH), another crucial tripeptide that neutralizes reactive oxygen species (ROS). By upregulating antioxidant defenses, NAC scavenges ROS to mitigate cellular damage and also inhibits inflammation through the NF-κB signaling pathway.

To overcome the limitations of conventional NAC formulations, N-acetylcysteine has been introduced into novel drug delivery systems, NDDS. Using NDDS, drug stability is optimized, bioavailability is enhanced, targeted delivery is ensured, and dosage frequency is reduced. (4)

Types of NDDS developed for NAC

Various strategies have been developed to deliver NAC in a manner intended to overcome these limitations while providing maximum stability, bioavailability, and precision in directing certain tissues or organs.

• Liposomes: Longer half-life; targeted medication administration; improved bioavailability; pulmonary administration for respiratory conditions; and intravenous administration for systemic antioxidant effects.
• Nanoparticle-Based Systems: The stability of specific tissues is enhanced through enhanced cellular uptake, thereby enhancing the effectiveness of drugs in treating neurodegenerative disorders and cardiovascular diseases.
• Hydrogel Systems: Systemic healing and inflammation control are facilitated by high biocompatibility, localized delivery, and reduced side effects in wound healing applications.
• Microsphere Delivery: Formulations with extended-release profiles reduce dosing frequency, enhance patient compliance, and are suitable for injectable and oral use in chronic diseases.
• Solid Lipid Nanoparticles (SLNs): Formulations for ARDS, hepatic disorders, and NAC, which are enzymatically degraded, are used to protect NAC, enhance solubility, and provide controlled drug release.
• Polymeric Nanocarriers: Therapeutic therapy utilizing variable kinetics can effectively reduce inflammatory disorders, enhancing efficacy and reducing chemoresistance in cancer patients.
• Transdermal Patches: Relief from systemic oxidative stress and pain is achieved through non-invasive delivery, prolonged drug delivery, and effective management of oxidative stress.
• Inhalable Formulations: The rapid onset of systemic exposure to fibrosis, a condition characterized by inflammation and a high local drug concentration, has been linked to various health issues.
• Oral Sustained-Release Tablets: The patient's plasma concentration fluctuations can be minimized by reducing the frequency of dosing, improving patient compliance, and potentially treating chronic liver diseases and neurological disorders.

NAC's therapeutic potential is significantly enhanced through tailored delivery methods, facilitated by NDDS. These innovative methods enhance bioavailability, distribution, and prolonged release, making NAC-based treatments more efficient and patient-friendly, thereby enhancing the efficacy of NAC-based treatments.(3,5,6)

Formulation Strategies to Enhance NAC Delivery

Encapsulation and Nanoparticle Delivery

Encapsulating the medication in nanoparticle carriers is one of the most promising methods to enhance NAC delivery. These nanoparticles can improve NAC's solubility, prevent degradation, and enable regulated release.

• Polymeric Nanoparticles: Poly (lactic-co-glycolic acid) (PLGA) is a biocompatible and biodegradable polymer, and encapsulated NAC within the nanoparticles, and then slowly releasing it in the chemical will help decrease the frequency of dosing as the therapeutic level of NAC would be maintained in the systemic circulation for extended periods. In addition, PLGA nanoparticles may be conjugated with surface ligands that specifically bind to specific receptors on the target cells so that they can selectively deliver to particular organs, such as brain or lung tissue.(7)
• Liposomes: The liposomes, which are structures of phospholipid bilayer, have been widely studied for the encapsulation of NAC. Liposomes shield NAC from degradation and thus improve its stability and bioavailability when encapsulating both hydrophilic and hydrophobic drugs. Furthermore, liposomes can be designed to exploit the affinity of the cell membrane to lipophilic compounds to enhance cellular uptake.
• Targeted Delivery: Liposomes can be functionalized with targeting moieties, such as peptides or antibodies, to focus NAC on specific cell types or tissues. This technique of targeting is particularly helpful in cancer treatment because NAC might be administered directly to the tumour cells to decrease oxidative stress without causing any danger to the normal cells.
• Solid Lipid Nanoparticles (SLNs): SLNs are prepared using solid lipids, which have been studied (8,9)as NAC carriers. SLNs enhance the solubility of NAC, which is generally poorly soluble in water, while providing a controlled release profile. They have the advantage of low toxicity and can be administered either locally or systemically.
• Nano liposomes and Nanogels: These systems use both lipids and nanoparticles to combine their respective benefits. They can be made for regulated and prolonged release, and they provide NAC with improved stability and bioavailability. Moreover, the gel-like matrix of nanogels can hold NAC in a stable, release-controlled form.(10,11)

Microencapsulation

Microencapsulation means the encapsulation of NAC into a biocompatible polymer matrix or microcapsule. This makes NAC suitable for sustained-release formulations since the microencapsulation prevents oxidation while permitting gradual release.

These techniques enhance NAC's stability, controls release rate, and protects it from gastrointestinal degradation. It can be administered orally, adapted for nasal or pulmonary delivery, using materials like alginates, chitosan, and cellulose derivatives.

Co-Encapsulation with Other Compounds

NAC might sometimes be co-encapsulated with other medications to enhance delivery or potentiate its action. For example, NAC may act in concert with other antioxidants or anti-inflammatory agents.

Chemotherapy: Co-encapsulation of NAC with chemotherapy drugs such as doxorubicin or cisplatin may enhance the efficacy of the chemotherapy by decreasing oxidative stress in the cancer cells, thereby protecting normal tissues from oxidative damage.(12)

Neurodegenerative Diseases: In cases of Alzheimer's and Parkinson's, a complete treatment might be achieved when NAC is combined with neuroprotective agents like resveratrol or curcumin. Technologies continue to advance.

Therapeutic Applications of NAC-Based NDDS

• Respiratory diseases: Liposomal aerosols and other inhalable NAC formulations directly target the lungs, changing conditions such as asthma and COPD. In diseases such as ARDS, these systems improve oxygenation, lessen inflammation, and decrease mucus viscosity.
• Neurodegenerative Disorders: In diseases such as Parkinson's and Alzheimer's, oxidative stress is targeted by NAC through nanoparticles designed to cross the blood-brain barrier. Functionalized liposomes and nanogels have shown promise in preclinical studies.
• Oncology: NDDS allows for targeted administration of NAC to tumours, thus inhibiting cancers caused by oxidative stress. Liposomes and nanoparticles loaded with NAC also help protect healthy tissues from oxidative damage, which improves the efficacy of chemotherapy treatments.
• Wound Healing: NAC-impregnated hydrogels and nanogels stimulate tissue regeneration and inhibit inflammation, thus accelerating wound healing. To optimize healing, stimuli-responsive systems respond to the wound's exudate and release NAC.
• Cardiovascular and Metabolic Diseases: Transdermal patches and polymeric nanoparticles enhance the bioavailability of NAC, helping to treat oxidative stress in diseases such as diabetes, hypertension, and atherosclerosis. These mechanisms reduce systemic inflammation and improve endothelial function.(8,9)

2. Advantages and limitations of NAC in novel drug delivery systems (NDDS)

The mucolytic, anti-inflammatory, and antioxidant properties have already put N-acetylcysteine in promising treatment scenarios for a broad spectrum of diseases. Problems with delivery, stability, and bioavailability often restrict the clinical usage of NAC. To bypass these restrictions and maximize the therapeutic potential of NAC, Novel Drug Delivery Systems, were developed. These systems include hydrogels, liposomes, and nanoparticles, among others. This section discusses the advantages and disadvantages of using NAC in NDDS. It concentrates on how such systems improve the drug's therapeutic effectiveness and areas where issues still lie.(13)

3. Future Perspectives and Opportunities of NAC in Novel Drug Delivery Systems (NDDS)

Numerous opportunities exist for N-acetylcysteine's therapeutic potential in novel drug delivery systems (NDDS), which will progress medical therapy in a variety of disease areas, from neurological disorders to cancer and respiratory-related ailments.  Since NAC's use in NDDS is still relatively new, technological advancements and continuing research are pushing the boundaries of what is feasible.  NAC therapies have a promising future thanks to the development of novel, targeted, biocompatible, and more efficient delivery systems.(14)

Technological Advancements in Drug Delivery Systems

The development of targeted drug delivery systems, or NDDS, is one significant advancement in the field of drug delivery.  These devices aim to enhance therapeutic efficacy and reduce side effects by accurately delivering medication to the site of action.  One such strategy is the use of nanoparticle-targeted nanoparticles, which are useful to cancer treatment because they may be delivered to particular cells or tissues that overexpress particular receptors.  Cell-specific targeting is an alternative approach that targets neurons affected by oxidative stress and inflammation, which can lead to neurodegenerative diseases like Parkinson's and Alzheimer's. It does this by using nanoparticles that can penetrate the blood-brain barrier.(15)

Smart nanocarriers and stimuli-responsive systems, which offer more precise control over drug release by releasing the drug in response to specific factors like pH, temperature, magnetic fields, or enzyme activity, are emerging fields in NDDS research.  PH-responsive systems, such as those loaded with NAC, release the medication in the acidic environment of tumor or inflammatory tissues to optimize therapeutic benefits and reduce side effects.(16)

Another application for temperature-responsive devices is site-specific drug delivery, which is particularly useful for conditions like rheumatoid arthritis.  Magnetic and ultrasonic-responsive systems, such as NAC-loaded magnetic nanoparticles, can increase the medication's localized effect by delivering it to the target area using an external magnetic field.

New Therapeutic Areas and Expanded Clinical Applications

There are several more areas where NAC's therapeutic potential in NDDS might be improved, despite the fact that it is currently being studied for the treatment of a number of disorders.  As new diseases are identified and our knowledge of existing disorders expands, NAC may play a significant role in many unexplored treatment areas.(17)

NAC has shown promise in a variety of applications, such as the treatment of cancer, neurological disorders, respiratory issues, and cardiovascular diseases.  It can be used as a stand-alone treatment or as an adjuvant to traditional treatments by altering the immune system, reducing oxidative stress, and increasing tumor sensitivity to other therapeutic medications.  NAC can also be delivered directly to tumor cells via liposomes or nanoparticles, reducing the side effects of traditional treatments.  Neurodegenerative conditions like multiple sclerosis, Parkinson's disease, and Alzheimer's disease may benefit from NAC because of their interest in it.  NAC may be able to overcome the challenge of passing through the blood-brain barrier (BBB) by entering the central nervous system (CNS) and starting to exert its neuroprotective effects thanks to drug delivery techniques based on nanoparticles.

By lowering inflammation and oxidative stress, NAC may provide long-term protection against brain damage. Inhalable formulations that increase the concentration of NAC at the site of action while reducing systemic side effects are possible when NAC-contained liposomes or nanoparticles enter the lung from the application site.  Targeting immune cells in the lungs, such as neutrophils and macrophages, which contribute to inflammation and oxidative damage in respiratory diseases, may lead to more effective treatments with fewer side effects. NAC also helps cardiovascular conditions, especially those linked to oxidative stress and inflammation.  It has been shown to protect endothelial cells, decrease platelet aggregation, and have vasodilatory effects.  Using NAC-loaded nanocarriers to target the vascular endothelium is one example of targeted cardiovascular therapy that may enhance therapeutic results and reduce systemic side effects.

Personalized Medicine and Patient-Centric Approaches

With the growing acceptance of customized treatment, this holds great promise for improving NAC's efficacy in NDDS.  Treatment is tailored to the patient's particular genetic makeup, illness profile, and response to medication.(18)

Biomarker-Driven NAC Therapy

By identifying individuals with a genetic susceptibility and stage of illness, biomarkers can direct NAC therapy in NDDS and enable more customised formulations.  By using pharmacogenomics to guide formulation selection, dose modification, and delivery strategies, this method can improve safety and efficacy.  By identifying patients who are most likely to benefit from NAC therapy, this method can enhance the therapeutic experience as a whole(19).

CONCLUSION

Because N-acetylcysteine (NAC) contains anti-inflammatory, mucolytic, neuroprotective, and antioxidant qualities, it may be used to treat conditions including cancer, cardiovascular disease, neurological disorders, and respiratory ailments.  Nevertheless, there are disadvantages to NAC administration, such as reduced bioavailability and restricted penetration into target locations.  NDDS technologies, such as hydrogels, liposomes, nanoparticles, and microspheres, can enhance the pharmacokinetic profile of NAC, increase its half-life, and target certain mechanisms of action.

Development of NAC-loaded NDDSs faces challenges in manufacturing, regulatory frameworks, and scalability. Regulatory bodies are creating standards to assess the quality, safety, and efficacy of these complex drug delivery systems. Collaboration among pharmaceutical companies, academic institutions, and regulatory agencies is essential to establish protocols for safe and efficient NAC-loaded NDDS. Accelerating research is necessary to reduce regulatory ambiguity and facilitate the clinical translation of innovative technologies. Large-scale production is complicated by specific methods and stringent quality control. Financial feasibility is impacted by production costs, patent protection, and market accessibility, while therapeutic use is contingent upon acceptance by patients and healthcare providers. Educating stakeholders on the benefits and risks of these technologies is vital for their adoption. Further research may lead to targeted treatments and personalized medications using smart carriers responsive to various biological stimuli.

Individual pharmacogenomics can optimize NAC therapies by enhancing their therapeutic potential and minimizing side effects. This personalized medicine approach aims to improve the safety and efficacy of NAC treatments for chronic diseases, particularly in cancer, neurological, respiratory, and cardiovascular disorders. NAC's role in managing oxidative stress and apoptosis may enhance chemotherapy effectiveness by improving tumor targeting and overcoming chemoresistance. Its delivery through liposomal and nanoparticle techniques further reduces systemic toxicity. Additionally, NAC has shown promise in treating neurodegenerative diseases like Parkinson's and Alzheimer's by decreasing oxidative damage in brain cells.

The blood-brain barrier presents challenges, but NAC can be administered to the brain using sophisticated delivery systems like liposomes and nanoparticles. It is beneficial for respiratory conditions such as ARDS, cystic fibrosis, and COPD due to its mucolytic and antioxidant properties. Specific delivery to the lungs minimizes systemic exposure, while NAC also reduces oxidative stress and inflammation in heart-related conditions. Future applications of NAC in novel drug delivery systems will require thorough clinical evaluation, multidisciplinary collaboration, and advancements in technology.

REFERENCES

1. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell Biology of Ischemia/Reperfusion Injury. Int Rev Cell Mol Biol . 2012 ;298:229. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3904795/
2. Li YL, Wang G, Wang BW, Li YH, Ma YX, Huang Y, et al. The potential treatment of N-acetylcysteine as an antioxidant in the radiation-induced heart disease. Cardiovasc Diagn Ther . 2024 Aug 31 ;14(4):509–24. Available from: https://cdt.amegroups.org/article/view/127892/html
3. Research Journal of Pharmaceutical Dosage Forms and Technology. Available from: https://rjpdft.com/HTMLPaper.aspx?Journal=Research%20Journal%20of%20Pharmaceutical%20Dosage%20Forms%20and%20Technology;PID=2023-15-1-7 
4. Sahasrabudhe SA, Terluk MR, Kartha R V. N-acetylcysteine Pharmacology and Applications in Rare Diseases—Repurposing an Old Antioxidant. Antioxidants. 2023 Jul 1 ;12(7):1316. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10376274/
5. Vrettos NN, Roberts CJ, Zhu Z. Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications. Pharmaceutics. 2021 Oct 1 ;13(10):1591. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8539558/
6. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. AAPS PharmSciTech. 2005 Oct 19 ;6(3). Available from: https://pubmed.ncbi.nlm.nih.gov/16353995/
7. Lu Y, Cheng D, Niu B, Wang X, Wu X, Wang A. Properties of Poly (Lactic-co-Glycolic Acid) and Progress of Poly (Lactic-co-Glycolic Acid)-Based Biodegradable Materials in Biomedical Research. Pharmaceuticals 2023, Vol 16, Page 454. 2023 Mar 17 16(3):454. Available from: https://www.mdpi.com/1424-8247/16/3/454/htm
8. Sahasrabudhe SA, Terluk MR, Kartha R V. N-acetylcysteine Pharmacology and Applications in Rare Diseases—Repurposing an Old Antioxidant. Antioxidants 2023, Vol 12, Page 1316. 2023 Jun 21  ;12(7):1316. Available from: https://www.mdpi.com/2076-3921/12/7/1316/htm
9. Raghu G, Berk M, Campochiaro PA, Jaeschke H, Marenzi G, Richeldi L, et al. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol. 2020 Dec 31;19(8):1202–24. 
10. Dejeu IL, Vica? LG, Marian E, Ganea M, Fren? OD, Maghiar PB, et al. Innovative Approaches to Enhancing the Biomedical Properties of Liposomes. Pharmaceutics 2024, Vol 16, Page 1525 . 2024 Nov 27  ;16(12):1525. Available from: https://www.mdpi.com/1999-4923/16/12/1525/htm
11. Lombardo D, Kiselev MA. Methods of Liposomes Preparation: Formation and Control Factors of Versatile Nanocarriers for Biomedical and Nanomedicine Application. Pharmaceutics . 2022 Mar 1  ;14(3):543. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8955843/
12. Muldoon LL, Wu YJ, Pagel MA, Neuwelt EA. N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models. J Neurooncol . 2015 Feb 1  ;121(3):433–40. Available from: https://pubmed.ncbi.nlm.nih.gov/25411097/
13. Varala R, Kotra V, Kanuri AK, Burra MR, Nyamathullah S. Nano drug delivery-benefits, limitations and future perspective. Nano and Medical Materials. 2023 Dec 12;244.
14. Khadam VKR, Singh RP, Prajapati D, Yunus M, Prajapat B, Rai SK, et al. An Updated Comprehensive Review on Novel Drug Delivery Systems (NDDS) In the Pharmaceuticals. Asian Journal of Pharmaceutical Research and Development . 2024 Feb 15  ;12(1):55–64. Available from: https://ajprd.com/index.php/journal/article/view/1349
15. Kochman U, Sitka H, Ku?niar J, Czaja M, Kozubek P, Besz?ej JA, et al. Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer’s Disease: A Review. Mol Neurobiol . 2025 Nov 19  ;63(1):75. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12627166/
16. Islam S, Ahmed MMS, Islam MA, Hossain N, Chowdhury MA. Advances in nanoparticles in targeted drug delivery–A review. Results in Surfaces and Interfaces . 2025 May 1;19:100529. Available from: https://www.sciencedirect.com/science/article/pii/S2666845925001163
17. Waris A, Ali A, Khan AU, Asim M, Zamel D, Fatima K, et al. Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders. Nanomaterials. 2022 Jul 1 ;12(13):2140. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9268720/
18. Su J, Yang L, Sun Z, Zhan X. Personalised Drug Therapy: Innovative Concept Guided With Proteoformics. Mol Cell Proteomics. 2024 Mar 1 ;23(3):100737. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10950891/
19. Sadowski M, Zawieja E, Chmurzynska A. The impact of N?acetylcysteine on lactate, biomarkers of oxidative stress, immune response, and muscle damage: A systematic review and meta?analysis. J Cell Mol Med . 2024 Dec 1  ;28(23):e70198. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11617117/